Continuation in the K12 Paul Calabresi Career Development Award for Clinical Oncology Program is determined yearly based upon satisfactory research progress, professional effort, academic grades, and attendance and participation in required events.
1. Professional Effort
♦ Calabresi Scholars are expected to devote 75% of their full-time effort (50% for surgeons), for two years, to the
training and clinical oncology research activities of the program. Scholars’ remaining effort may be devoted to
other clinical or academic pursuits consistent with the award. However, salary supplementation may not be from
federal funds unless specifically authorized by the federal program from which such funds are derived.
♦ Developing a successful cancer research career requires strong relationships with mentors and a research team.
Scholars will select three mentors, one primary mentor and two secondary mentors. Each mentoring team must
also include a practicing oncology MD. All mentors must be pre-approved by the K12 Program’s leadership.
Please click here for a list of approved mentors.
3. Program Milestones
♦ Within each Scholar’s career development plan, he/she will be
4. Didactic Coursework and Research Seminars
♦ This K12 Program includes a comprehensive didactic program in translational research methods including the
A. Principles of Cancer Biology (MD Scholars)/Introduction to Multidisciplinary Clinical Oncology
B. Methods in Clinical Cancer Research
C. Translational Cancer “omics” and the Path to Personalized Medicine
D. Principles of Targeted Cancer Drug Discovery and Development
E. Methods and Outcomes in Cancer Population Sciences
F. Cancer Immunotherapy: Lessons Learned and the Path Forward
Additionally, all Scholars will be required to take Ethical Issues in Clinical Research which meets requirements for Responsible Conduct in Research and attend workshops and seminars.
5. Three Areas of Research Focus
♦ The K12 Paul Calabresi Clinical & Translational Oncology Training Program will emphasize three key areas of
research training in specific pathways:
A. Drug discovery/development with a focus on small molecule drug development
B. Cancer immunotherapy including immunoglobulin, vaccine, and cellular therapies
C. Population sciences driven by cancer epidemiology, health behavior research, and implementation science
Each Scholar will choose one of these pathways.
For more information on these focus areas, please click here.
6. Laboratory & Clinical Rotations
♦ Short Laboratory Rotations: In order to provide a breadth of applied experience required in conducting
patient-oriented translational research, all Scholars will be required to complete one or more six-week laboratory
rotations relevant to the track they have selected and/or career development goals that they have established.
Many of these rotations are linked with key shared resources and are intended to provide the Scholar with the
opportunity to acquire specific technical expertise.
♦ Short Clinical Rotations: Scholars will be required to
participate in clinic-based research rotations as well. The
purpose of these rotations is to provide exposure and
experience in clinical investigation, as well as a focused
exposure to particular types of cancer patients. As part of the
K12 Program, MD Scholars may participate up to three half-day
clinics as either short rotations (six weeks) or during longitudinal
training for the duration of the Program. MD Scholars will be
expected to treat patients in the Phase I clinic for at least one of
these half day clinics and can then chose up to two other
multidisciplinary disease clinics. PhD Scholars will be required
to do at least three clinical research-related rotations.
♦ In Depth Clinical and Laboratory Training: Beginning in Quarter 2 or Quarter 3 of the first year of the
Scholar’s training program, he/she will immerse in a longitudinal clinical and laboratory experience that will
last for the remainer of the time the Scholar is in the program. These experiences will
form the foundation to complete the required milestones. Since the focus of the Program is primarily on the
development of a patient-oriented researcher, it is not expected that the MD Scholars will become basic science
researchers, but rather will learn to use assays, new technologies, and analyses that will enable the evaluation of
pertinent clinical research questions in the laboratory. The Scholars will be expected to be familiar with the
conduct, quality control, and interpretation of assays pertinent to their clinical research protocol. Likewise, PhD
Scholars are expected to draw upon their clinical observations to formulate more informed correlative study
designs. The proportions of laboratory and clinical involvement may differ between these two classes
of Scholars, but all will participate in both activities during the longitudinal training period.
7. National Meeting
♦ K12 Clinical Oncology Scholars will be required to attend a national professional meeting each year.
Grant Citations: All presentations and publications related to research funded by the K12 Paul
Calabresi Clinical & Translational Oncology Training Program must cite the appropriate grant
award. The NIH funding acknowledgement for all publications and projects is:
“This publication was supported by the National Cancer Institute of the National Institutes of
Health, Grant Number K12 CA157688. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the NIH."